poster

A Combination of Olanzapine and Samidorphan in Adults With Schizophrenia and Bipolar I Disorder: Overview of Clinical Data

Objectives: Olanzapine effectively treats schizophrenia and bipolar I disorder (BD-I); however, its use is hindered by significant weight gain. A combination of olanzapine and samidorphan...

10/08/2020

A Systematic Literature Review of Schizophrenia Clinical Practice Guidelines: Recommendations on use of Long-acting Injectable Anti-psychotic Medications

Background and Objectives: Many clinical practice guidelines (CPGs) on the treatment of schizophrenia have been updated. Aiming to review current CPGs, focusing specifically on long-actin...

10/08/2020

Challenges and Considerations in Design of a Placebo-Controlled, Double-Blind, Randomized-Withdrawal Study Evaluating the Efficacy and Safety of JZP-258 for the Treatment of Idiopathic Hypersomnia

No treatment is approved for idiopathic hypersomnia (IH). A retrospective chart review (Leu-Semenescu, et al. Sleep Med. 2016;17:38-44) demonstrated effectiveness of sodium oxybate (SXB) ...

10/08/2020

A randomized, placebo-controlled trial to evaluate the efficacy and safety of AR19 (amphetamine sulfate) in adults with attention-deficit/hyperactivity disorder

Background: AR19 is a pellets-in-capsule, immediate-release amphetamine sulfate investigational formulation with physical and chemical barriers designed to resist manipulation to deter sn...

10/08/2020

All-cause Healthcare Resource Utilization and Costs Among Patients With Episodic or Chronic Migraine and Comorbid Depression and/or Anxiety

Objective: This real-world retrospective cohort study evaluated healthcare resource utilization (HCRU) and costs for adult patients with episodic migraine (EM) or chronic migraine (CM) an...

10/08/2020

Antidepressant and Psychotherapy Treatment among Patients With Major Depressive Disorder and an Elevated PHQ-9 Score

Background The PHQ-9 measures depression symptom severity and is recommended for use in clinical practice among patients with major depressive disorder (MDD). Objective To describe treat...

10/08/2020

An Assessment of the Impact of Prior Antipsychotic Treatment on the Duration of Treatment with RBP-7000 during a Long-Term Safety Study

Introduction: RBP-7000 (PERSERIS™) is a once-monthly subcutaneous extended-release risperidone formulation approved for the treatment of schizophrenia in adults, designed to deliver clini...

10/08/2020

Characteristics of Commercially Insured Patients Initiated on Esketamine Nasal Spray in a Real-World Setting

BACKGROUND: Esketamine nasal spray was approved for adults with treatment-resistant depression on 03/05/2019. Real-world data on patients initiated on esketamine is limited. METHODS: Adu...

10/08/2020

Bipolar Disorder Treatment Patterns in the United States: A Retrospective Claims Database Study

Background: The objective of this retrospective study was to describe treatment patterns among patients with bipolar disorder.

10/08/2020

Characteristics of young adults with schizophrenia using Colorado`s All Payer Claims Database (CO-APCD)

Background Schizophrenia (SCZ) is most likely to develop in young adulthood. Using data from a single state, we describe the demographic and clinical characteristics of young adults in t...

10/08/2020

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products